LTS congratulates its partner TEVA Pharmaceutical Industries Ltd. for the US launch of ZECUITY®, the first and only transdermal patch system for the treatment of acute migraine.
Approximately 36 million people in the United States suffer from migraine and its various characteristics like throbbing pain, sensitivity to light, sensitivity to sound and nausea.
ZECUITY® is a prescription medicine used for the acute treatment of migraine with or without aura in adults.
As TEVA´s partner LTS contributed to the development of ZECUITY®. LTS produces ZECUITY® in its production sites in Andernach/Germany und West Caldwell/USA.